Abstract:730 Background: Gastrointestinal stromal tumor (GIST) is a rare mesenchymal tumor arising from the gastrointestinal tract, characterized by a high predominance of the elderly population. Imatinib is the standard first-line therapy for advanced GIST with a median survival of around 4 years in pivotal clinical trials. However, clinical data for the elderly population is not known well. The aim of this study is to evaluate the efficacy and safety of imatinib for advanced GIST in the elderly population in comparison with the non-elderly population. Methods: We extracted clinical data of patients with advanced GIST treated with imatinib as first-line therapy at our institution between January 2010 and July 2023. Progression-free survival (PFS), overall survival (OS), objective response rate (ORR) and adverse events (AEs) were assessed and compared between the elderly group (age: ≥ 70 years, E group) and the non-elderly group (age: < 70 years, NE group). Multivariable analyses were performed using Cox proportional hazard models to evaluate the prognostic significance of age groups. Results: A total of 91 patients were included in this analysis with 32 patients in the E group and 59 patients in the NE group with a median follow-up duration of 39.8 months. Patient characteristics were as follows (the E group vs. the NE group): median age 76 (70–90) vs. 54 (29–69) years, male: 50% vs. 56%, performance status 0: 19% vs. 63%, disease status (: 47% vs. 44%), stomach primary 44% vs. 34%, KIT mutation (exon 11: 50% vs. 61%), and maximum tumor diameter (≥8cm: 66% vs. 51%). The proportion of patients with a reduced starting dose of imatinib was significantly higher in the E group (34% vs. 2%, p <0.0001). Median PFS in the E group and the NE group were 29.4 months and 60.0 months (HR=2.04, log-rank p=0.035). Median OS in the E group and the NE group were 91.5 months and not reached (HR=2.74, log-rank p=0.02). ORR was 53% in the elderly group and 66% in the non-elderly group (p=0.32). In for OS, age was not an independent prognostic factor (HR=2.09, p=0.14) with a significant independent prognostic factor of disease status (unresectable/initially metastatic vs. recurrent (reference): HR=3.58, p=0.03). The occurrence of ≥ grade 2 non-hematologic AEs was more common in the elderly group compared to the non-elderly group (78% vs. 32%, p<0.001). Conclusions: The elderly population with advanced GIST may achieve a survival period comparable to that observed in pivotal trials with imatinib. Even with reduced doses of imatinib, careful monitoring is necessary because of the high frequency of non-hematologic ≥ grade 2 AEs in the elderly population.

Imatinib use for gastrointestinal stromal tumors among older patients in Japan and Taiwan

To Compare the Efficacy of Sunitinib and Imatinib Following Cytoreductive Resection in GIST Patients with Progression on Imatinib: A Multi-Center Controlled Study.

A retrospective analysis of the efficacy and safety of imatinib in elderly patients with advanced gastrointestinal stromal tumor.

Efficacy and safety of adjuvant post-surgical therapy with imatinib in gastrointestinal stromal tumor patients with high risk of recurrence: interim analysis from a multicenter prospective clinical trial]

Efficacy and Safety of the Imatinib in the Treatment of 73 Gastrointestinal Stromal Tumors

Imatinib in Patients with Advanced Gastrointestinal Stromal Tumours (Gists)

Clinical Efficacy and Safety of Sunitinib After Imatinib Failure in Japanese Patients with Gastrointestinal Stromal Tumor

Clinical outcomes of second‐generation tyrosine kinase inhibitors versus imatinib in older patients with CML

Clinical Outcomes of Imatinib Dose Escalation Versus Sunitinib in First-Line Imatinib-Failure Gastrointestinal Stromal Tumour

Imatinib Mesylate Alone for Refractory Advanced Gastrointestinal Stromal Tumor

Post-operative imatinib in patients with intermediate or high risk gastrointestinal stromal tumor.

Observation of domestic imatinib on advanced gastrointestinal stromal tumors

Adjuvant imatinib in high‐risk resected gastrointestinal stromal tumors: Merely delaying the inevitable?

Current status of and future prospects for the treatment of unresectable or metastatic gastrointestinal stromal tumours

Cost-Effectiveness Analysis of Tyrosine Kinase Inhibitors in Gastrointestinal Stromal Tumor: A Systematic Review

Efficacy and Safety of Sunitinib in Chinese Patients with Imatinib-Resistant or -Intolerant Gastrointestinal Stromal Tumors.

Real World Treatment Patterns of Gastrointestinal Stromal Tumor Patients

Characteristics and predictors of outcomes with neoadjuvant imatinib in gastrointestinal stromal tumors: Real-world data from a large patient registry.

A systematic review and meta‐analysis of neoadjuvant imatinib use in locally advanced and metastatic gastrointestinal stromal tumors

Postoperative Imatinib in Patients with Intermediate Risk Gastrointestinal Stromal Tumor

Risk of Disease Recurrence and Mortality in Gastrointestinal Stromal Tumor (gist) Patients Receiving Short-Term Versus Long-Term Imatinib Adjuvant Therapy: A Chart Review Analysis.